Circulating levels of galectin‐9 are a potential biomarker of survival in advanced non‐small‐cell lung cancer
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27758 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Guilherme Vieira de Mendonça Filho und 3 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Galectins, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Background
The immune system is recognized to have therapeutic potential to destroy cancer cells. Soluble T‐cell immunoglobulin mucin domain‐3 (sTIM‐3) and its ligand galectin 9 (Gal‐9) cause suppression of cytokine production, cell cycle arrest and cell death. sTIM‐3 and Gal‐9 levels may have prognostic implications in non‐small‐cell lung cancer (NSCLC) patients.
Methods
This prospective cohort study was performed at Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Pernambuco, Brazil. Fifty‐eight patients were diagnosed with advanced NSCLC from January 2019 to January 2020.
Results
The age median was of 64.0 years. Soluble galectin‐9 (sGal‐9) levels in the smokers compared to nonsmoker patients ( p < 0.0001). By using the receiver operating characteristic curve, we found that a baseline of 1694 pg/mL (cutoff). sGAL9 with specificity (72.2%), sensitivity (83.2%) and area under the curve = 0.8497 ( p < 0.0004). Until 18.2 months, 46.8% and 72.9% were alive in the sGAL9 low and sGAL9 high groups, respectively (log‐rank test; p = 0.02). The median survival was 15.9 months for sGAL9 low (≤1694 pg/mL).
Conclusion
This study indicated an association of tobacco with the release of circulating sGal‐9 levels and the accuracy of sGal‐9 as a potential biomarker predictive of survival time in advanced NSCLC patients. Furthermore, sGal‐9 has may be a potential therapeutic target in the advanced NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil.
- Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo City, São Paulo, Brazil.
- Research Clinical Department, Hospital de Câncer de Pernambuco (HCP), Recife, Brazil.
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Filho, G. V. M., Costa, G. J., Martins, M. R., & Torres, L. C. (2024). Circulating levels of galectin‐9 are a potential biomarker of survival in advanced non‐small‐cell lung cancer. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27758
Vancouver
Filho GVM, Costa GJ, Martins MR, Torres LC. Circulating levels of galectin‐9 are a potential biomarker of survival in advanced non‐small‐cell lung cancer. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27758
BibTeX
@article{Filho2024,
author = {Filho, Guilherme Vieira de Mendonça and Costa, Guilherme Jorge and Martins, Mario R and Torres, Leuridan C},
title = {Circulating levels of galectin‐9 are a potential biomarker of survival in advanced non‐small‐cell lung cancer},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27758}
}
EUVIMED